{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Height&page=14",
    "query": {
      "intervention": "Height",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 464,
    "total_pages": 47,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Height&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Height&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T09:31:13.973Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01284335",
      "title": "A Safety Study in Participants With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "LY573636",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2008-07",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2019-01-10",
      "last_synced_at": "2026-10-23T09:31:13.973Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Denver, Colorado + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01284335"
    },
    {
      "nct_id": "NCT04411186",
      "title": "A Trial of Adding Lung Protective Strategies to Existing Enhanced Recovery After Surgery (ERAS) Protocols and Its Effects on Improving Post-Operative Lung Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colorectal Surgery",
        "Hepatobiliary Surgery"
      ],
      "interventions": [
        {
          "name": "Standard Enhanced Recovery After Surgery (ERAS) Protocol",
          "type": "PROCEDURE"
        },
        {
          "name": "ERAS and 5 Lung Protective Interventions",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2021-03-22",
      "completion_date": "2021-09-21",
      "has_results": true,
      "last_update_posted_date": "2024-07-05",
      "last_synced_at": "2026-10-23T09:31:13.973Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04411186"
    },
    {
      "nct_id": "NCT01855386",
      "title": "The Role of Non-Alcoholic Fatty Liver Disease in Gestational Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gestational Diabetes Mellitus in Pregnancy"
      ],
      "interventions": [
        {
          "name": "Subjects with Gestational Diabetes",
          "type": "OTHER"
        },
        {
          "name": "Controls without Gestational Diabetes",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 126,
      "start_date": "2013-01",
      "completion_date": "2018-09",
      "has_results": false,
      "last_update_posted_date": "2018-11-08",
      "last_synced_at": "2026-10-23T09:31:13.973Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01855386"
    },
    {
      "nct_id": "NCT05472545",
      "title": "Dyadic Neurofeedback for Development of Healthy Emotion Regulation in Youth",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Emotional Regulation"
      ],
      "interventions": [
        {
          "name": "Neurofeedback",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Oklahoma State University Center for Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "14 Years and older · Female only"
      },
      "enrollment_count": 180,
      "start_date": "2023-03-13",
      "completion_date": "2025-10-13",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-10-23T09:31:13.973Z",
      "location_count": 1,
      "location_summary": "Tulsa, Oklahoma",
      "locations": [
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05472545"
    },
    {
      "nct_id": "NCT01933594",
      "title": "Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Romidepsin",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Romidepsin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2014-05-05",
      "completion_date": "2018-04-16",
      "has_results": true,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-10-23T09:31:13.973Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01933594"
    },
    {
      "nct_id": "NCT02250521",
      "title": "McGRATH MAC Video Laryngoscope",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Intubation; Difficult"
      ],
      "interventions": [
        {
          "name": "McGrath MAC enhanced direct laryngoscope",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2014-08",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2018-11-09",
      "last_synced_at": "2026-10-23T09:31:13.973Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02250521"
    },
    {
      "nct_id": "NCT04138875",
      "title": "A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PTLD",
        "Lymphoid Tumor",
        "Hematopoietic/Lymphoid Cancer",
        "Plasmacytic Hyperplasia PTLD",
        "Infectious Mononucleosis",
        "Florid Follicular Hyperplasia PTLD",
        "Polymorphic PTLD",
        "Monomorphic PTLD",
        "Classical Hodgkin Lymphoma Type PTLD"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-01",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2022-06-23",
      "last_synced_at": "2026-10-23T09:31:13.973Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Rochester, Minnesota",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04138875"
    },
    {
      "nct_id": "NCT02238327",
      "title": "Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease",
        "HIV",
        "Emphysema"
      ],
      "interventions": [
        {
          "name": "blood draw",
          "type": "PROCEDURE"
        },
        {
          "name": "questionnaires",
          "type": "PROCEDURE"
        },
        {
          "name": "Lung function testing",
          "type": "PROCEDURE"
        },
        {
          "name": "Six-Minute walk test",
          "type": "PROCEDURE"
        },
        {
          "name": "Quantitative CT scans",
          "type": "RADIATION"
        },
        {
          "name": "Nasal secretion and cell collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiogram",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 232,
      "start_date": "2014-09",
      "completion_date": "2020-03-02",
      "has_results": false,
      "last_update_posted_date": "2020-10-08",
      "last_synced_at": "2026-10-23T09:31:13.973Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02238327"
    },
    {
      "nct_id": "NCT05732623",
      "title": "Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Colorectal Cancer",
        "Early Onset Colorectal Cancer",
        "Diet Habit",
        "Risk Reduction"
      ],
      "interventions": [
        {
          "name": "Semi Quantitative Food Frequency Questionnaire (SQFFQ)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "San Raffaele University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 2300,
      "start_date": "2022-12-05",
      "completion_date": "2035-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-10-23T09:31:13.973Z",
      "location_count": 2,
      "location_summary": "Denver, Colorado • Chicago, Illinois",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05732623"
    },
    {
      "nct_id": "NCT07169279",
      "title": "Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Achondroplasia"
      ],
      "interventions": [
        {
          "name": "Infigratinib is provided as a single dose of minitablets for oral administration",
          "type": "DRUG"
        },
        {
          "name": "Infigratinib is provided as sprinkle capsules for daily oral administration",
          "type": "DRUG"
        },
        {
          "name": "Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QED Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "32 Months",
        "sex": "ALL",
        "summary": "0 Years to 32 Months"
      },
      "enrollment_count": 77,
      "start_date": "2025-11-19",
      "completion_date": "2032-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-10-23T09:31:13.973Z",
      "location_count": 3,
      "location_summary": "Oakland, California • Baltimore, Maryland • Madison, Wisconsin",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07169279"
    }
  ]
}